http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 03 Sep 2026 02:31:06 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Downgrades/Rothschild+Redburn+Downgrades+Moderna+%28MRNA%29+to+Sell/27020983.html <p>Rothschild Redburn analyst Simon Baker downgraded Moderna (NASDAQ: MRNA) from Neutral to Sell with a price target of $81.00 (from $40.00).</p><p>The analyst comments: “On 19 August 2026, Moderna and Merck & Co (Buy) announced the interim, headline results for the phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda in patients with completely resected stage IIB-IV melanoma, saying in the release:</p><p>“At a pre-specified interim analysis, intismeran in combination with Keytruda as adjuvant therapy demonstrated statistically significant and clinically meaningful improvements in RFS and DMFS compared with Keytruda alone for patients with completely resected stage IIB, IIC, III or IV cutaneous http://www.streetinsider.com/Downgrades/Rothschild+Redburn+Downgrades+Moderna+%28MRNA%29+to+Sell/27020983.html Thu, 03 Sep 2026 02:31:06 -0400 MRNA http://www.streetinsider.com/Analyst+Comments/Rothschild+Redburn+Downgrades+Moderna+%28MRNA%29+to+Sell/27020983.html <p>Rothschild Redburn analyst Simon Baker downgraded Moderna (NASDAQ: MRNA) from Neutral to Sell with a price target of $81.00 (from $40.00).</p><p>The analyst comments: “On 19 August 2026, Moderna and Merck & Co (Buy) announced the interim, headline results for the phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda in patients with completely resected stage IIB-IV melanoma, saying in the release:</p><p>“At a pre-specified interim analysis, intismeran in combination with Keytruda as adjuvant therapy demonstrated statistically significant and clinically meaningful improvements in RFS and DMFS compared with Keytruda alone for patients with completely resected stage IIB, IIC, III or IV cutaneous http://www.streetinsider.com/Analyst+Comments/Rothschild+Redburn+Downgrades+Moderna+%28MRNA%29+to+Sell/27020983.html Thu, 03 Sep 2026 02:31:06 -0400 MRNA http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Press+Releases/Moderna+to+Present+at+Upcoming+Conferences+in+September+2026/27008671.html <p><strong id="dateline">CAMBRIDGE, MA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / September 1, 2026 / </strong>Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:</p><ul style="list-style-type:disc;"><li><p>Morgan Stanley 24^th Annual Global Healthcare Conference, on Monday, September 14 at 10:00 a.m. ET</p></li><li><p>Bernstein Insights: Healthcare Leaders and Disruptors 3^rd Annual Healthcare Forum, on Wednesday, September 23at 8:50 a.m. ET</p></li></ul><p>A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website at <a rel="nofollow" href="https://pr.report/9osrdGtP">investors.modernatx.com</a>.</p><p>A replay of each webcast will be archived on Moderna's website for http://www.streetinsider.com/Press+Releases/Moderna+to+Present+at+Upcoming+Conferences+in+September+2026/27008671.html Tue, 01 Sep 2026 07:00:00 -0400 MRNA http://www.streetinsider.com/ACCESS+Newswire/Moderna+to+Present+at+Upcoming+Conferences+in+September+2026/27008671.html <p><strong id="dateline">CAMBRIDGE, MA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / September 1, 2026 / </strong>Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:</p><ul style="list-style-type:disc;"><li><p>Morgan Stanley 24^th Annual Global Healthcare Conference, on Monday, September 14 at 10:00 a.m. ET</p></li><li><p>Bernstein Insights: Healthcare Leaders and Disruptors 3^rd Annual Healthcare Forum, on Wednesday, September 23at 8:50 a.m. ET</p></li></ul><p>A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website at <a rel="nofollow" href="https://pr.report/9osrdGtP">investors.modernatx.com</a>.</p><p>A replay of each webcast will be archived on Moderna's website for http://www.streetinsider.com/ACCESS+Newswire/Moderna+to+Present+at+Upcoming+Conferences+in+September+2026/27008671.html Tue, 01 Sep 2026 07:00:00 -0400 MRNA http://www.streetinsider.com/Investing/BioNTech+drops+10%25+on+mRNA+trial+failure%2C+highlighting+Moderna+contrast/26993987.html <p data-path-to-node="0">Investing.com -- BioNTech SE (NASDAQ: BNTX) shares tumbled 10% in Friday, rapidly unwinding the gains the stock had accumulated during a sector-wide mRNA rally just days prior. The selloff was triggered by the company’s announcement that it has terminated a Phase 2 trial for its mRNA cancer vaccine in colorectal cancer due to futility—a stark reality check for investors hoping the mRNA oncology revolution would be a rising tide that lifts all boats. </p> <p id="p-rc_8896de0309020010-25" data-path-to-node="2">The timing of the setback could not be more vivid. Last week, Moderna and Merck reported a landmark Phase 3 success for their mRNA vaccine http://www.streetinsider.com/Investing/BioNTech+drops+10%25+on+mRNA+trial+failure%2C+highlighting+Moderna+contrast/26993987.html Fri, 28 Aug 2026 09:46:58 -0400 BNTX MRNA http://www.streetinsider.com/Investing/BioNTech+drops+10%25+on+mRNA+trial+failure%2C+highlighting+Moderna+contrast/26993987.html <p data-path-to-node="0">Investing.com -- BioNTech SE (NASDAQ: BNTX) shares tumbled 10% in Friday, rapidly unwinding the gains the stock had accumulated during a sector-wide mRNA rally just days prior. The selloff was triggered by the company’s announcement that it has terminated a Phase 2 trial for its mRNA cancer vaccine in colorectal cancer due to futility—a stark reality check for investors hoping the mRNA oncology revolution would be a rising tide that lifts all boats. </p> <p id="p-rc_8896de0309020010-25" data-path-to-node="2">The timing of the setback could not be more vivid. Last week, Moderna and Merck reported a landmark Phase 3 success for their mRNA vaccine http://www.streetinsider.com/Investing/BioNTech+drops+10%25+on+mRNA+trial+failure%2C+highlighting+Moderna+contrast/26993987.html Fri, 28 Aug 2026 09:46:58 -0400 BNTX MRNA http://www.streetinsider.com/General+News/BioNTech+drops+10%25+on+mRNA+trial+failure%2C+highlighting+Moderna+contrast/26993987.html <p data-path-to-node="0">Investing.com -- BioNTech SE (NASDAQ: BNTX) shares tumbled 10% in Friday, rapidly unwinding the gains the stock had accumulated during a sector-wide mRNA rally just days prior. The selloff was triggered by the company’s announcement that it has terminated a Phase 2 trial for its mRNA cancer vaccine in colorectal cancer due to futility—a stark reality check for investors hoping the mRNA oncology revolution would be a rising tide that lifts all boats. </p> <p id="p-rc_8896de0309020010-25" data-path-to-node="2">The timing of the setback could not be more vivid. Last week, Moderna and Merck reported a landmark Phase 3 success for their mRNA vaccine http://www.streetinsider.com/General+News/BioNTech+drops+10%25+on+mRNA+trial+failure%2C+highlighting+Moderna+contrast/26993987.html Fri, 28 Aug 2026 09:46:58 -0400 BNTX MRNA http://www.streetinsider.com/General+News/BioNTech+drops+10%25+on+mRNA+trial+failure%2C+highlighting+Moderna+contrast/26993987.html <p data-path-to-node="0">Investing.com -- BioNTech SE (NASDAQ: BNTX) shares tumbled 10% in Friday, rapidly unwinding the gains the stock had accumulated during a sector-wide mRNA rally just days prior. The selloff was triggered by the company’s announcement that it has terminated a Phase 2 trial for its mRNA cancer vaccine in colorectal cancer due to futility—a stark reality check for investors hoping the mRNA oncology revolution would be a rising tide that lifts all boats. </p> <p id="p-rc_8896de0309020010-25" data-path-to-node="2">The timing of the setback could not be more vivid. Last week, Moderna and Merck reported a landmark Phase 3 success for their mRNA vaccine http://www.streetinsider.com/General+News/BioNTech+drops+10%25+on+mRNA+trial+failure%2C+highlighting+Moderna+contrast/26993987.html Fri, 28 Aug 2026 09:46:58 -0400 BNTX MRNA http://www.streetinsider.com/Upgrades/Argus+Upgrades+Moderna+%28MRNA%29+to+Buy/26993019.html (Updated - August 28, 2026 7:30 AM EDT) <p>Argus analyst John Eade upgraded Moderna (NASDAQ: MRNA) from Hold to Buy with a price target of $180.00.</p><p>The analyst comments "We are raising our rating on Moderna Inc. (NYSE: MRNA) to BUY from HOLD. The company, which develops therapeutics and vaccines based on messenger RNA for the treatment of infectious and cardiovascular diseases, rare diseases, immunological conditions, and cancer, has five products currently approved for human use. One of these products is one of the three approved COVID-19 vaccines in the U.S., one is a lower-dose COVID-19 vaccine, another is a recently approved http://www.streetinsider.com/Upgrades/Argus+Upgrades+Moderna+%28MRNA%29+to+Buy/26993019.html Fri, 28 Aug 2026 07:30:23 -0400 MRNA http://www.streetinsider.com/Analyst+Comments/Argus+Upgrades+Moderna+%28MRNA%29+to+Buy/26993019.html (Updated - August 28, 2026 7:30 AM EDT) <p>Argus analyst John Eade upgraded Moderna (NASDAQ: MRNA) from Hold to Buy with a price target of $180.00.</p><p>The analyst comments "We are raising our rating on Moderna Inc. (NYSE: MRNA) to BUY from HOLD. The company, which develops therapeutics and vaccines based on messenger RNA for the treatment of infectious and cardiovascular diseases, rare diseases, immunological conditions, and cancer, has five products currently approved for human use. One of these products is one of the three approved COVID-19 vaccines in the U.S., one is a lower-dose COVID-19 vaccine, another is a recently approved http://www.streetinsider.com/Analyst+Comments/Argus+Upgrades+Moderna+%28MRNA%29+to+Buy/26993019.html Fri, 28 Aug 2026 07:30:23 -0400 MRNA http://www.streetinsider.com/Hot+Comments/Argus+Upgrades+Moderna+%28MRNA%29+to+Buy/26993019.html (Updated - August 28, 2026 7:30 AM EDT) <p>Argus analyst John Eade upgraded Moderna (NASDAQ: MRNA) from Hold to Buy with a price target of $180.00.</p><p>The analyst comments "We are raising our rating on Moderna Inc. (NYSE: MRNA) to BUY from HOLD. The company, which develops therapeutics and vaccines based on messenger RNA for the treatment of infectious and cardiovascular diseases, rare diseases, immunological conditions, and cancer, has five products currently approved for human use. One of these products is one of the three approved COVID-19 vaccines in the U.S., one is a lower-dose COVID-19 vaccine, another is a recently approved http://www.streetinsider.com/Hot+Comments/Argus+Upgrades+Moderna+%28MRNA%29+to+Buy/26993019.html Fri, 28 Aug 2026 07:30:23 -0400 MRNA